Tipping the scales

GLP-1 drugs are set to go mainstream with one in eight US adults currently using them, oral versions being launched and prices dropping. A recent survey shows 12% of US adults using GLP-1 drugs, up from 6% a year ago. GLP-1s are indicated to treat diabetes, obesity and several ‘co-morbidities’ including heart failure. Adoption is highest among women and 50-64 year olds. Yet, affordability remains a hurdle – half of users report cost concerns. These cost concerns will likely decrease as the largest branded producers, Eli Lilly and Novo Nordisk, are cutting prices and there is ample availability of lower-priced copycats. The expected launch of oral versions (or ‘weight-loss pills’) in 2026 could accelerate uptake. Beyond healthcare, the ripple effect may hit food and beverage industries as consumers reduce their intake and shift habits.

Source: KFF, November 2025.